Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation

Author:

DeLurgio David B.1,Crossen Karl J.ORCID,Gill Jaswinder2ORCID,Blauth Christopher2ORCID,Oza Saumil R.3,Magnano Anthony R.3,Mostovych Mark A.3,Halkos Michael E.1ORCID,Tschopp David R.4,Kerendi Faraz4,Taigen Tyler L.5,Shults Christian C.6,Shah Manish H.6ORCID,Rajendra Anil B.7ORCID,Osorio Jose7ORCID,Silver Jonathan S.8ORCID,Hook Bruce G.8ORCID,Gilligan David M.9ORCID,Calkins Hugh10ORCID

Affiliation:

1. Emory University, St. Joseph’s Hospital, Atlanta, GA (D.B.D., M.E.H.). Cardiology Associates Research, LLC Tupelo, MS (K.J.C.).

2. Guy’s and St. Thomas Hospital, London, United Kingdom (J.G., C.B.).

3. St. Vincent’s HealthCare, Jacksonville, FL (S.R.O., A.R.M., M.A.M.).

4. Austin Heart PLLC, TX (D.R.T., F.K.).

5. Summa Health System, Akron, OH (T.L.T.).

6. Medstar Washington Hospital Center, Washington, DC (C.C.S., M.H.S.).

7. Grandview Medical Center, Birmingham, AL (A.B.R., J.O.).

8. Lahey Clinic, Burlington, MA (J.S.S., B.G.H.).

9. Virginia Cardiovascular Specialists, Richmond, VA (D.M.G.).

10. Johns Hopkins Medicine, Baltimore, MD (H.C.).

Abstract

Background: The limited effectiveness of endocardial catheter ablation (CA) for persistent and long-standing persistent atrial fibrillation (AF) treatment led to the development of a minimally invasive epicardial/endocardial ablation approach (Hybrid Convergent) to achieve a more comprehensive lesion set with durable transmural lesions. The multicenter randomized controlled CONVERGE trial (Convergence of Epicardial and Endocardial Ablation for the Treatment of Symptomatic Persistent AF) evaluated the safety of Hybrid Convergent and compared its effectiveness to CA for persistent and long-standing persistent AF treatment. Methods: One-hundred fifty-three patients were randomized 2:1 to Hybrid Convergent versus CA. Primary effectiveness was freedom from AF/atrial flutter/atrial tachycardia absent new/increased dosage of previously failed/intolerant class I/III antiarrhythmic drugs through 12 months. Primary safety was major adverse events through 30 days. CONVERGE permitted left atrium size up to 6 cm and imposed no limits on AF duration, making it the only ablation trial to substantially include long-standing persistent–AF, that is, 42% patients with long-standing persistent–AF. Results: Of 149 evaluable patients at 12 months, primary effectiveness was achieved in 67.7% (67/99) patients with Hybrid Convergent and 50.0% (25/50) with CA ( P =0.036) on/off previously failed antiarrhythmic drugs and in 53.5% (53/99) versus 32.0% (16/50; P =0.0128) respectively off antiarrhythmic drugs. At 18 months using 7-day Holter, 74.0% (53/72) Hybrid Convergent and 55% (23/42) CA patients experienced ≥90% AF burden reduction. A total of 2.9% (3/102) patients had primary safety events within 7 days, and 4.9% (5/102) between 8 and 30 days postprocedure. No deaths, cardiac perforations, or atrioesophageal fistulas occurred. All but one primary safety event resolved. Conclusions: The Hybrid Convergent procedure has superior effectiveness compared to the CA for the treatment of persistent and long-standing persistent atrial fibrillation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01984346.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3